Related Experiment Video
Updated: Jan 27, 2026

Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Targeting Trop-2 in solid tumors: future prospects
Saif Zaman1, Hassan Jadid2, Aaron C Denson2
1Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Abstract:
Trop-2 is a transmembrane glycoprotein that is upregulated in all cancer types independent of baseline levels of Trop-2 expression. Trop-2 is an ideal candidate for targeted therapeutics due to it being a transmembrane protein with an extracellular domain overexpressed on a wide variety of tumors as well as its upregulated expression relative to normal cells. As a result, several Trop-2-targeted therapeutics have recently been developed for clinical use, such as anti-Trop-2 antibodies and Trop-2-targeted antibody-drug conjugates (ADC). Subsequently, multiple early-phase clinical trials have demonstrated safety and clinical benefit of Trop-2-based ADCs across multiple tumor types. This includes clinical benefit and tolerability in tumor types with limited treatment options, such as triple-negative breast cancer, platinum-resistant urothelial cancer, and small-cell lung cancer. In this review, we elaborate on all clinical trials involving Trop-2.
Insights
Trop-2 targeted therapies, including antibody-drug conjugates (ADCs), show promise across various cancers. Clinical trials demonstrate Trop-2 ADCs offer safety and benefit, even in difficult-to-treat tumors like triple-negative breast cancer.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- Trop-2 is a transmembrane glycoprotein overexpressed in many cancer types.
- Its expression is higher on tumor cells than normal cells, making it a target for cancer therapy.
- Trop-2 targeted therapeutics, including antibody-drug conjugates (ADCs), are emerging treatments.
Purpose of the Study:
- To review clinical trials involving Trop-2 targeted therapies.
- To summarize the safety and efficacy of Trop-2 based ADCs.
- To highlight the potential of Trop-2 as a therapeutic target in oncology.
Main Methods:
- Literature review of clinical trials involving Trop-2.
- Analysis of data on Trop-2 targeted antibody-drug conjugates (ADCs).
- Evaluation of safety and clinical benefit across various tumor types.
Main Results:
- Trop-2 targeted ADCs have demonstrated safety and clinical benefit in early-phase trials.
- Positive results observed in difficult-to-treat cancers such as triple-negative breast cancer, platinum-resistant urothelial cancer, and small-cell lung cancer.
- Trop-2 expression is consistently upregulated across diverse cancer types.
Conclusions:
- Trop-2 is a validated target for developing novel cancer therapeutics.
- Trop-2 based ADCs represent a promising therapeutic strategy with demonstrated clinical activity.
- Further clinical investigation of Trop-2 targeted agents is warranted across a spectrum of malignancies.
Related Concept Videos
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Structures of Solids
Network Covalent Solids
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
Molecular and Ionic Solids
Molecular Solids
Molecular crystalline solids, such as ice, sucrose (table sugar), and iodine, are solids that are composed of neutral molecules as their constituent units. These molecules are held together by weak intermolecular forces such as London dispersion forces, dipole-dipole interactions, or hydrogen bonds, which...
Molecular Comparison of Gases, Liquids, and Solids
Energy Bands in Solids
Band Formation:
When atoms are brought close together, as in a solid, these discrete energy levels begin to split due to the overlap of electron orbitals from adjacent atoms. This split occurs because of the Pauli exclusion principle, which states...

